Neurosense Therapeutics is trading 5.57% up now at $0.40 amid broader biotech-sector momentum, with XBI up 2.06% and no confirmed company-specific announcement or late-breaking catalyst identified.
- Shares closed at $0.38 on August 25, 2026.
- Investors are focused on the August 26 shareholder meeting, where approval of a potential 1-for-4 to 1-for-40 reverse split will be considered.